Latest News and Press Releases

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2DLBCL is an...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys® pTau181 plasma test demonstrate...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosisThe trial...

Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Mitgliedern des Verwaltungsrates bestätigt 38....

Adoption de toutes les propositions du Conseil d’administrationRéélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...

Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed38th...

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA)Late-breaking...

Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388Collaboration will complement Roche's...

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase III...